Stocks Bristol-Myers Squibb Co

More

  • NEW YORK/ ATLANTA, Oct 5- The Pacific trade deal agreed on Monday, which grants biotechnology drug producers less protection than offered by the United States, could put more downward pressures on the costly drugs' pricing in the industry's most lucrative market. The United States and 11 trading partners, including Mexico, Japan, Canada and Australia, wrapped up...

  • Your first look for Friday Thursday, 1 Oct 2015 | 6:23 PM ET

    The "Fast Money" traders give their final thoughts of the day.

  • *Two-drug combination to cost $256,000 a year. Oct 1- The U.S. Food and Drug Administration on Thursday approved the first combination of two drugs that help the immune system fight cancer, a therapy regimen that could cost $256,000 a year. Bristol-Myers Squibb Co said the FDA had given the green light to combine its immuno-oncology drugs Opdivo and Yervoy to...

  • ZURICH, Sept 27- Roche' s new immune-system boosting cancer drug has given positive results in tests on patients suffering from some lung and bladder cancers, according to data released on Sunday at the European Cancer Congress in Vienna that the company hopes will help it win quick regulatory approval. Roche, the largest maker of cancer drugs, is banking on...

  • Sept 26- Bristol-Myers Squibb's immunotherapy drug Opdivo extended kidney cancer survival rates by more than two years in a late-stage trial, setting it up to be used beyond melanoma and lung cancer. The U.S. company said in July the study was stopped early because its drug was more effective than Novartis' established product Afinitor, but detailed results...

  • NEW YORK, Sept 24- Deutsche Bank AG must face a U.S. government lawsuit seeking to recoup more than $190 million over an alleged tax fraud 15 years ago, after a federal judge on Thursday turned down the German's bank's request to dismiss the case. The government accused Deutsche Bank of using shell companies to avoid capital gains taxes on Bristol-Myers Squibb Co...

  • Sept 21- Gilead Sciences Inc is edging closer to the approval of the first drug to fight all forms of hepatitis C as the drugmaker's experimental combination showed high rates of effectiveness in four late-stage studies. The combination reduces the need for genotyping and potential confusion about which regimen works in which patients, UBS AG's Matthew...

  • Your first look for Monday Friday, 18 Sep 2015 | 5:48 PM ET

    The "Fast Money" traders look at the areas you should be watching going into the new week.

  • It also sends a lofty message to cross-town rival Novartis and other drugmakers that Roche, the world's biggest cancer drug company, is determined to retain its leadership of the $100 billion- a-year oncology market, despite mounting competition. Roche said its decision to erect "Building 1," as the tower is prosaically called, is motivated by a dearth of space at...

  • Lightning Round: Perfect stock for young investors Tuesday, 15 Sep 2015 | 6:55 PM ET
    Mad Money Lightning Round

    Jim Cramer gives his take quickly on caller favorite stocks, including this stock that is a great pick for young investors.

  • Your first look for Thursday Wednesday, 9 Sep 2015 | 6:26 PM ET

    The "Fast Money" traders discuss what's on their radar.

  • Top trader Najarian sees upside for Bristol Myers Wednesday, 9 Sep 2015 | 12:35 PM ET
    Bristol-Myers Squibb R&D headquarters.

    CNBC "Halftime Report" trader Jon Najarian bought shares of Bristol Myers after spotting unusual activity in the options market.

  • LONDON, Sept 3- Giving cheap aspirin to cancer patients may turbo-charge the effectiveness of expensive new medicines that help their immune systems fight tumours, experiments on mice suggest. One reason is that cancer cells often produce large amounts of the molecule prostaglandin E2, which turns down the immune system's normal attack response to tumour...

  • These battered stocks are China-proof Tuesday, 1 Sep 2015 | 12:55 PM ET
    Inside a Buffalo Wild Wings location.

    Experienced investors use China-driven market selloffs to buy these quality companies.

  • Early movers: GAS, CMG, ANF, BAC, ANF, BMY & more Monday, 24 Aug 2015 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer: Fed who? Stocks you need to be buying now Wednesday, 19 Aug 2015 | 6:13 PM ET
    Google headquarters in Mountain View, Calif., is viewed in this photo.

    Jim Cramer has had enough complaining! Instead of worrying about the market downturn, he lists the stocks that should be bought.

  • 3 plays on rocky biotechnology sector Tuesday, 18 Aug 2015 | 7:47 PM ET
    Pfizer headquarters in New York.

    Despite some shakiness in the last month, the biotech sector offers some buying opportunities, "Fast Money" traders said.

  • Cramer Remix: Here's the problem with Apple Tuesday, 4 Aug 2015 | 7:03 PM ET
    Jim Cramer speaks with Apple Inc. CEO Tim Cook on the 10th Anniversary of Mad Money.

    The “Mad Money” host Jim Cramer gives his take on Apple’s recent decline.

  • Cramer: Rare biotechs that stumped me Tuesday, 4 Aug 2015 | 6:35 PM ET
    Biotech pharma

    Jim Cramer went back to the drawing board and presented his research on the rare biotechs that stumped him last month.

  • Roche CEO warns on high pharma valuations Thursday, 23 Jul 2015 | 6:26 AM ET

    Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.